Efficacy and Safety Study of Dietary Supplements in Chronic Smokers Having Mild to Moderate Hyperlipidemia
Chronic Smokers, Hyperlipidemia
About this trial
This is an interventional prevention trial for Chronic Smokers focused on measuring Dietary supplements, Cotinine level, Malondialdehyde, Chronic smokers, Hyperlipidemia
Eligibility Criteria
Inclusion Criteria:
Men > 20 years
Chronic cigarette/ beedi smoker (2-3 packets/day since last 3 years or more) with mild to moderate hyperlipidemia (LDL ranging 160-189 mg/dL, TC >200 mg/dL and/or HDL-C <40 mg/dL)
Being mentally competent and able to understand all study requirements and sign the informed consent form.
Exclusion Criteria:
Patients with Chronic obstructive pulmonary disease (COPD)
Women
Patients with severe liver, renal, cardiac or brain diseases.
Unable to complete follow up.
Subjects on any medication like diuretics.
Allergic to any medication.
With a history of alcohol and/or drug abuse.
Sites / Locations
- Sreenivasa Clinic Diabetic Research Center
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Placebo Comparator
Experimental
Experimental
Experimental
Placebo
BioTurmin
BioTurmin-WD
MaQxan
Capsules containing 250 mg of placebo, two times a day
Capsules containing 250 mg of BioTurmin (Curcuma longa rhizomes extract), two times a day
Capsules containing 250 mg of BioTurmin-WD (water dispersible curcuminoids), two times a day
Capsules containing 10 mg of MaQxan (Tagetes erecta flower extract), two times a day